All In Biotech

Drug Trial Radar · NCT06900192

A Multicenter Phase 1 Study of Orca-Q in Primary Progressive Multiple Sclerosis

A Multicenter Phase 1 Study of Allogeneic Hematopoietic Cell Transplantation for Primary Progressive Multiple Sclerosis Using Orca-Q, an Engineered Donor Graft Derived From Mobilized Peripheral Blood

Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

10

Planned (sponsor's estimate)

Start

Mar 2027

Primary completion

Jun 2028

Study completion Dec 2032

Sponsor

Lead sponsor
Orca Biosystems, Inc.Industry
Sponsor type
Industry
First posted
Mar 28, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A study of allogeneic hematopoietic cell transplantation (alloHCT) with Orca-Q for the treatment of primary progressive multiple sclerosis (PPMS).

Conditions

  • Primary Progressive Multiple Sclerosis
  • Multiple Sclerosis
  • Multiple Sclerosis, Primary Progressive

Interventions

  • Orca-QBiological

    Allogeneic (donor) stem cell graft

  • myeloablative regimenDrug

    Myeloablative regimen of busulfan, fludarabine, and thiotepa.

  • TacrolimusDrug

    Graft-versus-host disease (GVHD) prevention

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Severe acute graft-versus-host-disease-free survivalTime frame: Up to 6 months after infusion

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.